116 related articles for article (PubMed ID: 4036958)
21. Erythroblastic and/or megakaryoblastic leukemia in Down syndrome: treatment with low-dose arabinosyl cytosine.
Tchernia G; Lejeune F; Boccara JF; Denavit MF; Dommergues JP; Bernaudin F
J Pediatr Hematol Oncol; 1996 Feb; 18(1):59-62. PubMed ID: 8556372
[TBL] [Abstract][Full Text] [Related]
22. The results of treatment of selected patients with ANLL with low-dose Ara-C.
Pawelski S; Brodzki LM; Gepner-Woźniewska M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(1):71-4. PubMed ID: 2472330
[TBL] [Abstract][Full Text] [Related]
23. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
24. Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients.
Tilly H; Castaigne S; Bordessoule D; Sigaux F; Daniel MT; Monconduit M; Degos L
Cancer; 1985 Apr; 55(8):1633-6. PubMed ID: 3978558
[TBL] [Abstract][Full Text] [Related]
25. Low-dose cytosine arabinoside therapy in a patient with myelofibrosis during transformation to acute non-lymphocytic leukemia.
Jensen MK; Johansen P; Ahlbom G
Acta Med Scand; 1986; 219(1):129-31. PubMed ID: 3953312
[TBL] [Abstract][Full Text] [Related]
26. Cell kinetic effect of low dose arabinosyl cytosine.
Baccarani M; Tazzari PL; Motta MR; Rizzi S; Fanin R; Fasola G; Damiani D; Dinota A; Tura S
Br J Haematol; 1987 Sep; 67(1):33-7. PubMed ID: 3663521
[TBL] [Abstract][Full Text] [Related]
27. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.
Vidarsson B; Abonour R; Williams EC; Woodson RD; Turman NJ; Kim K; Mosher DF; Wiersma SR; Longo WL
Leuk Lymphoma; 2001 Apr; 41(3-4):321-31. PubMed ID: 11378544
[TBL] [Abstract][Full Text] [Related]
28. [High-dose cytosine arabinoside treatment of leukemia with special reference to the optimal number of doses].
Sampi K; Maseki N; Kumai R; Kaneko Y; Sakurai M; Hattori M
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2595-8. PubMed ID: 2774589
[TBL] [Abstract][Full Text] [Related]
29. [Value of high-dose cytosine-arabinoside in the treatment of resistant acute leukemia].
Witz F; Olive D; Lederlin P; Bordigoni P; Troussard X; Grosbois B; Schaison G; Cornu G
Presse Med; 1987 Feb; 16(4):159-62. PubMed ID: 2950446
[TBL] [Abstract][Full Text] [Related]
30. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
Li JM; Shen Y; Wu DP; Liang H; Jin J; Chen FY; Song YP; Song EY; Qiu XF; Hou M; Qiu ZC; Shen ZX
Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759
[TBL] [Abstract][Full Text] [Related]
31. Low-dose cytosine arabinoside (LD-Ara C) treatment in dysmyelopoietic syndromes (DMPS) and acute myelogenous leukemia (AML).
Jehn U; Göldel N; Vehling-Kaiser U
Anticancer Res; 1987; 7(3 Pt B):505-8. PubMed ID: 3477124
[TBL] [Abstract][Full Text] [Related]
32. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
[TBL] [Abstract][Full Text] [Related]
33. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
Nowrousian MR; Seeber S; Miller AA; Anders C; Ohl S; Schmidt CG
Onkologie; 1985 Feb; 8(1):26-32. PubMed ID: 3885117
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy for acute non-lymphocytic leukemia with low-dose cytosine arabinoside (Ara-C).
Lin SF; Liu HW; Chen TP
Nihon Ketsueki Gakkai Zasshi; 1990 Feb; 53(1):45-50. PubMed ID: 2330805
[TBL] [Abstract][Full Text] [Related]
35. [Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia].
Esumi N; Todo S; Arakawa S; Imashuku S
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):951-8. PubMed ID: 3963859
[TBL] [Abstract][Full Text] [Related]
36. Treatment of acute myeloid leukemia developing after a myelodysplastic phase with low dose arabinosyl cytosine.
Ho AD; Schwarz CE; Hunstein W
Leuk Res; 1985; 9(10):1293-8. PubMed ID: 3865029
[TBL] [Abstract][Full Text] [Related]
37. Low-dose arabinosyl cytosine therapy of AML may be effective after failure of high or conventional doses.
Tertian G; Tchernia G; Léonard C; Miélot F; Avalos M; Mirica C; Brivet F; Dommergues JP
Nouv Rev Fr Hematol (1978); 1989; 31(4):311-3. PubMed ID: 2608442
[TBL] [Abstract][Full Text] [Related]
38. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia.
Estey E; Plunkett W; Dixon D; Keating M; McCredie K; Freireich EJ
Leukemia; 1987 Aug; 1(8):580-3. PubMed ID: 3669771
[TBL] [Abstract][Full Text] [Related]
39. Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase.
Im T; Yamane T; Mugitani A; Hiyoshi M; Park K; Tatsumi N
Int J Hematol; 1994 Oct; 60(3):215-23. PubMed ID: 7532031
[TBL] [Abstract][Full Text] [Related]
40. Influence of small doses cytosine arabinoside (Ara-C) on leukemic cells in vitro and in vivo. Results in patients with leukemia and myelodysplastic syndrome.
Kuliczkowski K; Kotlerek-Haus S; Frydecka I; Sedek K; Nowicka J
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):738-48. PubMed ID: 2436986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
